Samalizumab: Preliminary Phase I/II data

Preliminary data from an ongoing, dose-escalation Phase I/II trial showed that 18 of 21 evaluable patients with advanced B-CLL or MM who were treated with IV samalizumab achieved reductions of 81-98% ...